Join pharmaphorum for an insightful webinar, presented by EVERSANA INTOUCH, featuring Denise Dalton, vice president of ...

Aurion Biotech has launched its cell therapy Vyznova for serious eye disorder bullous keratopathy in Japan, its debut market, ...

The wide-ranging deal, worth up to $1 billion, covers multiple targets and disease areas and focuses on the discovery and ...

Novo Nordisk chief executive Lars Fruergaard Jørgensen was taken to task by US lawmakers over the price of the company's ...

Shares in Wave rose 53% after the trial data was announced, taking its market cap above the $1 billion threshold. The company ...

Phase 2 results with Wave Life Sciences' Duchenne muscular dystrophy candidate WVE-N531 pushed the company's share price to ...

Kisunla (donanemab) is the second in a new generation of amyloid-targeting medicines to reach the Japanese market after Eisai ...

The ESMO congress always disseminates the latest results of cancer research, a vibrant gathering and sharing of the latest data, communicating the next promising steps in oncological scientific ...

Zevra Therapeutics' Miplyffa has become the first medicine to be approved by the FDA for the ultra-rare genetic disorder ...

J&J said its latest bankruptcy bid is backed by around 83% of the 60,000-plus claimants cited in lawsuits, who are claiming ...

Kayfanda (odevixibat) is labelled in the EU to treat cholestatic pruritus – itching caused by impaired bile formation or flow ...

Dr Paul Campbell, head of software and AI at the MHRA, said in a recent webinar that AIaMD has the potential to "fix some of ...